Who we are
MetaHeps® has an ex-vivo blood test to exclude or clearly identify DILI in a patient with liver injury. It can also identify the causal drug of the DILI especially in a complex polymedication situation. MetaHeps thereby helps BioPharmaceutical companies and CROs to solve the risks of DILI for drugs in clinical development and in the market. All in an unrivalled way.
The Clinical Challenge
Solutions for BioPharma Industry
The MetaHeps Technology
MetaHeps has developed and offers the first and only in-vitro test to clearly identify the cause of suspected DILI.